Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of the antiviral agent famciclovir and the anticonvulsant gabapentin, utilized in the management of acute herpes zoster (shingles) and the prevention or treatment of postherpetic neuralgia (PHN). Famciclovir is a prodrug of penciclovir that inhibits viral DNA polymerase, thereby suppressing viral replication. Gabapentin acts by binding to the alpha-2/delta-1 subunit of voltage-gated calcium channels in the central nervous system, modulating the release of excitatory neurotransmitters to alleviate neuropathic pain. This specific combination is being studied by investigator Xiaguang Duan in clinical trials evaluating the additive efficacy of multimodal nerve blocks and pulsed radiofrequency for severe zoster-associated pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on famciclovir + gabapentin.